Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stimulate
- Development stage
- Unknown
- Lead developer
- Chongqing Jinsaixing Medical Technology
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Stimulate is a PEGDE-crosslinked hyaluronic acid hydrogel developed by Chongqing Jinsaixing Medical Technology for the correction of midface volume and contour deficiencies. Unlike traditional dermal fillers that typically use 1,4-butanediol diglycidyl ether (BDDE) as a cross-linking agent, Stimulate utilizes polyethylene glycol diglycidyl ether (PEGDE) to create its gel structure. This technology is intended to provide a biocompatible and stable scaffold for soft tissue augmentation. The product is currently in Phase 3 clinical development (NCT05543447), where it is being compared to Restylane Volyme to demonstrate non-inferiority in efficacy and safety for midface rejuvenation.
- Brand names
- Stimulate
- Other names
- PEGDE-crosslinked hyaluronic acid hydrogel
Beyond the preview
Go deeper on Stimulate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stimulate.